From migraine mechanisms to innovative therapeutic drugs

Neurology

Volumn 64, Issue 10 SUPPL. 2, 2005, Pages

  Silberstein, Stephen D ^a   Lipton, Richard B ^a   Ramadan, Nabih M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMIGRAINE AGENT; CALCITONIN GENE RELATED PEPTIDE; NONSTEROID ANTIINFLAMMATORY AGENT; SUBSTANCE P; VASOACTIVE INTESTINAL POLYPEPTIDE;

ALLODYNIA; EDITORIAL; HEADACHE; HUMAN; MIGRAINE; MIGRAINE AURA; NOCICEPTIVE RECEPTOR; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION; SPREADING CORTICAL DEPRESSION; TRIGEMINAL NERVE; VASODILATATION;

EID: 18844395308     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.64.10_suppl_2.s1     Document Type: Editorial

References (34)

1. Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nature Med 2002;8:136-142.
2. Uddman R, Edvinsson L, Ekman R, Kingman T, McCulloch J. Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. Neurosci Lett 1985;62:131-136.
3. Buzzi MG, Moskowitz MA, Shimizu T, Heath HH. Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology 1991;30:1193-1200.
4. Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated plasma extravasation in dura mater: effect of ergot alkaloids. A possible mechanism of action in vascular headache. Cephalalgia 1988;8:83-91.
5. Pappagalo M, Szabo Z, Esposito G, Lokesh A, Velez L. Imaging neurogenic inflammation inpatients with migraine headaches. Neurology 2002;52:274-275. Abstract.
6. Dimitriadou V, Buzzi MG, Theoharides TC, Moskowitz MA. Ultrastructural evidence for neurogenically mediated changes in blood vessels of the rat dura mater and tongue following antidromic trigeminal stimulation. Neuroscience 1992;48:187-203.
7. Strassman AM, Raymond SA, Burstein R. Sensitization of meningeal sensory neurons and the origin of headaches. Nature 1996;384:560-564.
8. Moskowitz MA, Cutrer FM. Sumatriptan: a receptor-targeted treatment for migraine. Ann Rev Med 1993;44:145-154.
9. Nozaki K, Boccalini P, Moskowitz MA. Expression of c-fos-like immunoreactivity in brainstem after meningeal irritation by blood in the subarachnoid space. Neuroscience 1992;49:669-680.
10. Kaube H, Keay K, Hoskin KL, Bandler R, Goadsby PJ. Expression of c-fos like immunoreactivity in the trigeminal nucleus caudalis and high cervical cord following stimulation of the sagittal sinus in the cat. Brain Res 1993;629:95-102.
11. Goadsby PJ, Hoskin KL. The distribution of trigeminovascular afferents in the non-human primate brain. J Anat 1997;190(pt 3):367-375.
12. Zagami AS, Goadsby PJ, Edvinsson L. Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. Neuropeptides 1990;16:69-75.
13. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990;28:183-187
14. Goadsby PJ, Edvinsson L. The trigeminovascular system in migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993;33:48-56.
15. Edvinsson L, Goadsby PJ. Neuropeptides in headache. Eur J Neurol 1998;5:329-341.
16. O'Connor TP, Van der Kooy D. Enrichment of vasoactive neuropeptide (calcitonin gene related peptide) in trigeminal sensory projection to the intracranial arteries. J Neurosci 1988;8:2468-2476.
17. O'Connor TP, Van der Kooy D. Pattern of intracranial and extracranial projections of trigeminal ganglion cells. J Neurosci 1986;6:2200-2207.
18. Doods H, Hallermayer G, Wu D, et al. Pharmacological profile of BIBN-4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 2000;129:420-423.
19. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 2004;55:19-26.
20. Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack: clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 2001;123:1703-1709
21. Potrebic S, Ahn AH, Skinner K, Fields HL, Basbaum AI. Peptidergic nociceptors of both trigeminal and dorsal root ganglia express serotonin ID receptors: implications for the selective antimigraine action of triptans. J Neurosci 2003;23:10988-10997.
22. Ji RR, Woolf CJ. Neuronal plasticity and signal transduction in nociceptive neurons: implications for the initiation and maintenance of pathological pain. Neurobiol Dis 2001;8:1-10.
23. Ji RR, Rupp F. Phosphorylation of transcription factor CREB in rat spinal cord after formalin-induced hyperalgesia: relationship to c-fos induction. J Neurosci 1997;17:1776-1785.
24. Samad TA, Moore KA, Sapirstein A, et al. Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 2001;410:471-475.
25. Hunt SP, Pini A, Evan G. Induction of c-fos like protein in spinal cord neurons following sensory stimulation. Nature 1987;328:1686-1704.
26. Ji RR, Befort K, Brenner GJ, Woolf CJ. ERK MAP kinase activation in superficial spinal cord neurons induces prodynorphin and NK-1 upregulation and contributes to persistent inflammatory pain hypersensitivity. J Neurosci 2002;22:478-485.
27. Iadarola MJ, Douglass J, Civelli O, Naranjo JR. Differential activation of spinal cord dynorphin and enkephalin neurons during hyperalgesia: evidence using cDNA hybridization. Brain Res 1988;455:205-212.
28. Mannion RJ, Costigan M, Decosterd I, et al. Neurotrophins: peripherally and centrally acting modulators of tactile stimulus-induced inflammatory pain hypersensitivity. Proc Natl Acad Sci USA 1999;96:9385-9390.
29. McCarson KE, Krause JE. NK-1 and NK-3 type tachykinin receptor mRNA expression in the rat spinal cord dorsal horn is increased during adjuvant or formalin-induced nociception. J Neurosci 1994;14:712-720.
30. Rich G, Yoder EJ, Moore SA. Regulation of prostaglandin H synthase-2 expression in cerebromicrovascular smooth muscle by serum and epidermal growth factor. J Cell Physiol 1998;176:495-505.
31. Ebersberger A, Averbeck B, Messlinger K, Reeh PW. Release of substance P, calcitonin gene-related peptide and prostaglandin E2 from rat dura mater encephali following electrical and chemical stimulation in vitro. Neuroscience 1999;89:901-907.
32. Krymchantowski AV. Naproxen sodium decreases migraine recurrence when administered with sumatriptan. Arq Neuropsiquiatr 2000;58: 428-430.
33. Krymchantowski AV, Barbosa JS. Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. Cephalalgia 2002;22:309-312.
34. Krymchantowski AV, Bigal ME. Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine. BMC Neurol 2004;4:10. (last accessed on April 3, 2005 at www.biomedcentral.com/content/pdf/1471-2377-4-10.pdf).